Equity Overview
Price & Market Data
Price: $0.35
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $214,560,144
Volume: 0
Performance Metrics
1 Week: 40.00%
1 Month: 40.00%
3 Months: 25.00%
6 Months: 32.08%
1 Year: 349,900%
YTD: 20.69%
Details
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.